Abstract:Introduction Contrary to classical belief, people affected by this disease are at greater risk of developing organic pathologies.This risk has a very complex origin: a greater exposure to risk factors and specific socioeconomic conditions, a high prevalence of risk behaviors, the use of antipsychotics, and a potential common genetic background. (Reynolds et al.Int. J.Neuropsychopharmacol.2021; 24 854–855, Suvisaari J et al. Curr Diab Rep. 2016 16). Multiple studies demonstrate that Schizophrenia confers a high endogenous risk of Diabetes. Before patients diagnosed with Schizophrenia start taking antipsychotics (Andreassen OA et al. Am J Psychiatry. 2017;174 616-617), they have an approximately 3 times higher risk of developing Diabetes compared to the general population. The risk increases 3.6 times after the initiation of antipsychotic treatment compared to drug naive patients(Annamalai A et al World J Diabetes. 2017 390-396) Objectives To study the association between Schizophrenia or other Psychotic Disorders and Diabetes Mellitus in a sample of patients diagnosed with Schizophrenia or other Psychotic Disorders. Methods This is a Descriptive and Cross-sectional Observational Study. Clinical Histories were reviewed and a personal or telephone interview was established to expand data related to the objectives of the study. The patients were recruited among the patients seen in the specific Severe Mental Disorder consultation who had a diagnosis of schizophrenia or other Psychotic Disorders, according to DSM 5-TR criteria. Results From a sample of 93 patients, 24 had Diabetes. The Prevalence of Diabetes in patients with Schizophrenia or other Psychotic Disorders was 25.8%. Of the patients without a diagnosis of Diabetes, 15 of them had values of Glycosylated Hemoglobin (HbA1c) for Prediabetes. Using the Chi-Square Test, statistically significant differences were found between the variable Main Psychiatric Medication and Diabetes. Patients treated with Clozapine, Aripiprazole and Olanzapine had a Prevalence of Diabetes of 40.9%, 33.3% and 28.5%, respectively. Conclusions Prevalence of Diabetes in our sample was 3.4 times higher than the 7.51% of the general population in Spain. This presumes a significant importance and impact on the health of these patients. The diabetic patients in our sample were diagnosed with Diabetes years after the diagnosis of the mental illness, which seems to indicate that the causes have to do with lifestyle, dietary habits, weight, and exposure to chronic antipsychotics. Premature death in schizophrenia has several explanations, being of special importance the development of cardiovascular disorders and Diabetes This can be due to many reasons, but it is worth highlighting the metabolic side effects of some antipsychotics and lifestyle. In this sense, it is essential to carefully monitor this group of patients. Disclosure of Interest None Declared

Disorders of glucose metabolism in medication-free patients with schizophrenia

Abnormal glucose metabolism is associated with clinical symptoms of adolescent-onset patients with first-episode drug-naive schizophrenia

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits.

The prevalence, risk factors and clinical correlates of diabetes mellitus in Chinese patients with schizophrenia

The prevalence and clinical characteristics of diabetes mellitus in Chinese inpatients with chronic schizophrenia: a multicenter cross-sectional study

Glucose Metabolism and Sex Hormones in Male Patients with Medication-naïve First-episode Schizophrenia: A Large-scale Cross-sectional Study

The Prevalence and Clinical-Demographic Correlates of Diabetes Mellitus in Chronic Schizophrenic Patients Receiving Clozapine.

Prevalence of diabetes and insulin resistance in patients with diagnosis of schizophrenia or other psicotic disorders

Retrospective Study on Hyperglycemia of Inpatients with Schizophrenia

Prevalence and risk factors for abnormal glucose metabolism in first-episode and drug-naïve major depressive disorder outpatients with comorbid anxiety: A cross-sectional study from a large sample of the Chinese Han population

Relationship Between Glycometabolism and Tardive Dyskinesia in Schizophrenia Patients

Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia

Prevalence and clinical correlates of abnormal glucose metabolism in young, first- episode and medication-naïve outpatients with major depressive disorder in China

Glucose metabolism, hippocampal subfields and cognition in first-episode and never-treated schizophrenia

Relationship Between Insulin Resistance, Dyslipidaemia and Positive Symptom in Chinese Antipsychotic-Naive First-Episode Patients with Schizophrenia

Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese

Analysis of the influencing factors for the cognitive deficits in schizophrenic patients with diabetes

Gender Differences in Prevalence and Associated Factors of Metabolic Syndrome in First-Treatment and Drug-Naïve Schizophrenia Patients.

Related factors of carotid atherosclerosis in patients with Schizophrenia and diabetes

Prevalence of Abnormal Glucose Regulation in Patients with Chronic Ischemic Heart Failure

Diabetes in late-life schizophrenia: Prevalence, factors, and association with clinical symptoms